HLA-C and cancer: JunB was identified as a central regulator of the immunosuppressive, non-inflamed TME, as it negatively correlated with antigen presentation by MHC molecules, immune cell recruitment, anti-cancer immune response, and immune checkpoint inhibitors, thereby contributing to an unfavorable prognosis of tumor patients.